2591 — Guangzhou Innogen Pharmaceutical Co Share Price
Last trade - 00:00- HK$24.21bn
- HK$24.22bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 27.93 | ||
| Price to Tang. Book | 27.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.82% | ||
| Return on Equity | -23.27% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- January 1st, 1970
- Incorporated
- December 5th, 2014
- Public Since
- August 15th, 2025
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 456,819,349
- Address
- GUANGZHOU, 510010
- Web
- https://www.innogenpharm.com/
- Phone
- +86 2058216265
- Auditors
- Ernst & Young
Similar to 2591
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ab&B Bio Tech Co JS
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:18 UTC, shares in Guangzhou Innogen Pharmaceutical Co are trading at HK$53.00. This share price information is delayed by 15 minutes.
Shares in Guangzhou Innogen Pharmaceutical Co last closed at HK$53.00 and the price had moved by over the past 365 days. In terms of relative price strength the Guangzhou Innogen Pharmaceutical Co share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreGuangzhou Innogen Pharmaceutical Co does not currently pay a dividend.
Guangzhou Innogen Pharmaceutical Co does not currently pay a dividend.
Guangzhou Innogen Pharmaceutical Co does not currently pay a dividend.
To buy shares in Guangzhou Innogen Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$53.00, shares in Guangzhou Innogen Pharmaceutical Co had a market capitalisation of HK$24.21bn.
Here are the trading details for Guangzhou Innogen Pharmaceutical Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2591
Based on an overall assessment of its quality, value and momentum Guangzhou Innogen Pharmaceutical Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guangzhou Innogen Pharmaceutical Co. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$53.00, shares in Guangzhou Innogen Pharmaceutical Co were trading -1.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Guangzhou Innogen Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$53.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Guangzhou Innogen Pharmaceutical Co's directors